Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560068 | 0.90 | OPRK1 (0.45) | EPHX2CYP2C9CYP2J2KDM1ARCOR1 | |
| SCHEMBL19327867 | 0.87 | LIPE (0.45) | SRD5A1MAPTLIPEEPHX2 | |
| SCHEMBL17560284 | 0.85 | EPHX2 (0.52) | SRD5A1LIPEEPHX2CYP2C9CYP2J2 | |
| SCHEMBL17554458 | 0.85 | GPR119 (0.56) | KDM1A | |
| SCHEMBL30389108 | 0.85 | GPR119 (0.56) | KDM1A | |
| SCHEMBL17560073 | 0.84 | KDM1A (0.45) | SRD5A1MAPTLIPEEPHX2CYP2C9 | |
| SCHEMBL19610351 | 0.84 | FAAH (0.52) | SRD5A1MAPTLMNAFAAH | |
| SCHEMBL17554391 | 0.83 | HRH3 (0.51) | DRD2DRD4DRD3KDM1ARCOR1 | |
| SCHEMBL17560027 | 0.82 | MAOB (0.55) | SRD5A1MAPTLIPE | |
| SCHEMBL17560111 | 0.81 | KDM1A (0.43) | MAPTLIPEKMT2AKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-01-22 | — | — | US | disclosed |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-09-14 | — | — | US | disclosed |
| EP-3189059-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034946-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993175-A1 | Thienopyrroles as histone demethylase inhibitors | IEO - Istituto Europeo di Oncologia Srl (IT) | 2016-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | KDM1A, KDM1B, KDM3A | SRD5A1 453/4885MAPT 3613/4885LIPE 1760/4885 |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1A, KDM1B, KDM3A | SRD5A1 453/4885MAPT 3613/4885LIPE 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.